- Home
- KIDS vs PLRX Comparison
KIDS vs PLRX Comparison
Compare KIDS & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIDS
- PLRX
- Stock Information
- Founded
- KIDS 2007
- PLRX 2015
- Country
- KIDS United States
- PLRX United States
- Employees
- KIDS N/A
- PLRX N/A
- Industry
- KIDS Medical/Dental Instruments
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- KIDS Health Care
- PLRX Health Care
- Exchange
- KIDS Nasdaq
- PLRX Nasdaq
- Market Cap
- KIDS 601.5M
- PLRX 680.3M
- IPO Year
- KIDS 2017
- PLRX 2020
- Fundamental
- Price
- KIDS $24.35
- PLRX $12.68
- Analyst Decision
- KIDS Buy
- PLRX Strong Buy
- Analyst Count
- KIDS 6
- PLRX 7
- Target Price
- KIDS $37.67
- PLRX $40.50
- AVG Volume (30 Days)
- KIDS 317.8K
- PLRX 485.5K
- Earning Date
- KIDS 03-05-2025
- PLRX 02-26-2025
- Dividend Yield
- KIDS N/A
- PLRX N/A
- EPS Growth
- KIDS N/A
- PLRX N/A
- EPS
- KIDS N/A
- PLRX N/A
- Revenue
- KIDS $189,673,000.00
- PLRX N/A
- Revenue This Year
- KIDS $39.26
- PLRX N/A
- Revenue Next Year
- KIDS $18.08
- PLRX N/A
- P/E Ratio
- KIDS N/A
- PLRX N/A
- Revenue Growth
- KIDS 33.47
- PLRX N/A
- 52 Week Low
- KIDS $21.02
- PLRX $10.22
- 52 Week High
- KIDS $35.99
- PLRX $18.00
- Technical
- Relative Strength Index (RSI)
- KIDS 45.67
- PLRX 47.63
- Support Level
- KIDS $23.55
- PLRX $10.35
- Resistance Level
- KIDS $25.45
- PLRX $11.07
- Average True Range (ATR)
- KIDS 1.26
- PLRX 0.55
- MACD
- KIDS -0.28
- PLRX 0.11
- Stochastic Oscillator
- KIDS 20.48
- PLRX 55.75
About KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.